Breast Cancer :: Avastin in Europe for women with metastatic breast cancer
Roche announced that their innovative cancer drug Avastin (bevacizumab) has been approved in Europe for the treatment of women with metastatic breast cancer.
Treatment
Health :: International health security issues – World Health Day 2007
A WHO background document will be used to help guide discussions and stir debate. The paper profiles eight issues linked to international health security, together with key points to focus the debate:
Circumcision :: Male circumcision should be part of a comprehensive HIV prevention package
In response to the urgent need to reduce the number of new HIV infections globally male circumcision should be recommended for the prevention of HIV infection.
Liver :: Estrogen protects liver after traumatic injury
Researchers have identified the receptor pathway used by estrogen to decrease liver injury after trauma and hemorrhage.
Cancer :: A sweet step toward new cancer therapies
By recognizing sugars, a technique developed by University of Michigan analytical chemist Kristina Hakansson sets the stage for new cancer diagnosis and treatment options.
Brain :: Neurophysiologist explores the mysteries of the human brain
“An accessible view of the inner workings of the human brain for the nonscientist reader … a masterful job of bridging the ever-widening gulf between science and the general public” said Margaret McFall-Ngai, professor, University of Wisconsin Madison School of Medicine and Public Health.
Accutane :: FDA’s Web Page Warning Against Buying Accutane
The U.S. Food & Drug Administration (FDA) is launching a special Web page to warn consumers about the dangers of buying isotretinoin (Accutane) online.
IBS :: FDA discontinues marketing of GI drug, Zelnorm, for safety reasons
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug.
Clotting Disorder :: FDA approves Ceprotin biologic to treat rare clotting disorder
The U.S. Food and Drug Administration (FDA) licensed Ceprotin, the first biologic treatment for patients with a rare genetic defect that can cause a potentially life-threatening clotting disorder.
Antibiotic :: European Medicines Agency recommends restricted use of Ketek
The European Medicines Agency (EMEA) has recommended restrictions on the use of Ketek (telithromycin) in three of its four approved indications.